AVI-7288 for Marburg

AVI-7288 FOR MARBURG

We are developing AVI-7288 for the treatment of Marburg virus infection under a contract with the U.S. Department of Defense managed by the Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office.

 
 
 
 
  • PROGRAM
  • DISCOVERY
  • preclinical
  • PHASE 1
  • PHASE 2
  • PHASE 3
 

INFECTIOUS DISEASES

  • AVI-7288
    MARBURG VIRUS
  • AVI-7537
    EBOLA VIRUS
  • AVI-7100
    INFLUENZA
  • VIRAL PMO-X
    DENGUE
  • BACTERIAL PPMO
    TB
  • UNDISCLOSED TARGET
 
 
 

RECENT PRESS RELEASES

 
 
 

Marburg hemorrhagic fever is a severe and often fatal disease endemic to Africa. Marburg is classified as a Category A bioterrorism agent by the Centers for Disease Control and Prevention, and has been designated as a material threat to national security and public health by the U.S. Department of Homeland Security.

AVI-7288 is designed to bind to viral RNA and inhibit the synthesis of the nucleocapsid protein (NP). NP supports the replication of the viral genetic material in an infected cell, and is also involved in the assembly of mature viruses. Inhibition of NP is intended to interrupt the viral lifecycle and stop or slow the spread of the disease to other cells in the body.

AVI-7288 is based on our proprietary next-generation PMOplus® chemistry, which is also used across our infectious disease pipeline, including our lead investigational candidate for influenza.

Clinical development of AVI-7288 is being conducted pursuant to the U.S. Food and Drug Administration’s Animal Efficacy Rule, which is designed to facilitate the development of new drug products for indications in which conducting controlled clinical trials to determine efficacy in humans may be unethical or unfeasible. According to this rule, marketing approval may be granted based on the demonstration of efficacy in relevant animal species and safety in healthy human subjects.